■这项研究的目的是调查新诊断为宫颈癌的患者的部位和特定转移数量与生存率的潜在关联。
■回顾性分析浙江省肿瘤医院2006年10月至2016年12月初诊宫颈癌器官转移患者的病历。使用Kaplan-Meier方法比较生存时间。使用单变量和多变量Cox比例风险模型鉴定与生存相关的变量。
■共确认了99例新诊断的器官转移性宫颈癌患者。中位随访时间为11.6个月(范围,0.5-114.7个月)。中位总生存期(OS)时间为11.7个月,1年、2年和5年OS率为48.2%,22.8%,12.6%,分别。器官转移最常见的部位是骨(36.8%),其次是肺(32.8%)和肝(24%)。在单变量分析中,骨转移的OS率优于内脏转移(P=0.013)。寡转移多于非寡转移(P=0.003),单器官转移多于多器官转移(P=0.016),肝转移比非肝转移差(P<0.001)。在多变量分析中,肝转移(风险比[HR]=4.02;95%置信区间[CI],1.15-14.05,P=0.029)与不良总生存率显着且独立相关。
■我们的数据显示转移部位与新诊断的器官转移性宫颈癌患者的总生存期相关,肝转移表明总体生存率特别差。应根据特定的转移部位对患者进行个体化治疗。
UNASSIGNED: The aim of this study was to investigate the potential associations of the sites and the number of specific metastases with survival in patients newly diagnosed with cervical cancer.
UNASSIGNED: Medical records of patients with organ metastases of newly diagnosed cervical cancer at Zhejiang Cancer Hospital from October 2006 to December 2016 were reviewed retrospectively. Survival times were compared using the Kaplan-Meier method. Variables associated with survival were identified using univariate and multivariate Cox proportional hazards models.
UNASSIGNED: A total of 99 patients with newly diagnosed organ metastatic cervical cancer were identified. Median follow-up was 11.6 months (range, 0.5-114.7 months). Median overall survival (OS) time was 11.7 months from diagnosis, with 1, 2, and 5-year OS rates of 48.2%, 22.8%, and 12.6%, respectively. The most common site of organ metastasis was bone (36.8%), followed by lung (32.8%) and liver (24%). In univariate analysis, OS rates were better for bone metastasis than visceral metastasis (P=0.013), oligometastasis than non-oligometastasis (P=0.003) and single organ metastasis than multiple organ metastases (P=0.016), while that for liver metastasis was poorer than non-liver metastases (P<0.001). In multivariate analysis, liver metastasis (hazard ratio [HR] =4.02; 95% confidence interval [CI], 1.15-14.05, P=0.029) was significantly and independently related to poor overall survival.
UNASSIGNED: Our data revealed the site of metastasis is associated with overall survival of patients with newly diagnosed organ metastatic cervical cancer, with liver metastasis signifying particularly poor overall survival. Individualized treatments should be administered to patients depending on the specific metastatic sites.